BridgeBio Pharma (NASDAQ:BBIO) Trading Up 9.3% - Should You Buy?

Key Points

• Shares jumped 9.3% to about $71.76 intraday, although trading volume (~1.27M shares) was roughly 60% below the average session volume.
• Analysts are broadly bullish — 23 Buy ratings versus 1 Sell and a consensus price target of $82.50, with multiple recent upgrades and higher targets from firms like HC Wainwright and Truist.
• Fundamentals are mixed: BridgeBio missed quarterly EPS (‑$1.00 vs. estimate of ‑$0.75) while revenue surged ~2521% year‑over‑year, and insiders have sold 227,095 shares in the past 90 days though they still own ~18.2% of the stock.

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) shot up 9.3% on Tuesday . The company traded as high as $70.49 and last traded at $71.7590. 1,265,413 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 3,135,348 shares. The stock had previously closed at $65.64.

Analyst Upgrades and Downgrades

BBIO has been the subject of a number of analyst reports. Barclays assumed coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 28th. They set an "overweight" rating for the company. HC Wainwright lifted their price target on BridgeBio Pharma from $90.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. William Blair started coverage on BridgeBio Pharma in a report on Tuesday. They issued an "outperform" rating for the company. Leerink Partners boosted their price target on BridgeBio Pharma from $75.00 to $86.00 and gave the stock an "outperform" rating in a research report on Monday, December 15th. Finally, Truist Financial increased their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $82.50.

BridgeBio Pharma Price Performance

The firm has a market capitalization of $14.41 billion, a P/E ratio of -19.75 and a beta of 1.13. The firm's fifty day moving average price is $73.44 and its 200-day moving average price is $65.56.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million during the quarter, compared to analysts' expectations of $150.71 million. BridgeBio Pharma's quarterly revenue was up 2521.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.40) earnings per share. Analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Maricel Apuli sold 510 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total transaction of $37,898.10. Following the transaction, the chief accounting officer directly owned 123,945 shares of the company's stock, valued at $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Thomas Trimarchi sold 13,600 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the sale, the chief financial officer owned 336,585 shares in the company, valued at approximately $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 227,095 shares of company stock worth $16,099,240. 18.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma during the first quarter valued at approximately $35,000. Envestnet Asset Management Inc. grew its position in BridgeBio Pharma by 204.1% in the second quarter. Envestnet Asset Management Inc. now owns 39,487 shares of the company's stock worth $1,705,000 after buying an additional 26,500 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of BridgeBio Pharma by 6.0% in the second quarter. Bank of Montreal Can now owns 9,865 shares of the company's stock valued at $426,000 after buying an additional 556 shares in the last quarter. Savant Capital LLC bought a new position in shares of BridgeBio Pharma in the second quarter valued at $218,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter valued at $693,000. Institutional investors and hedge funds own 99.85% of the company's stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.